Coultreon Biopharma Appoints Prista Charuworn, MD as Chief Medical Officer to Advance First-in-Class SIK3 Inhibitor COL-5671
核心洞察
Coultreon Biopharma (搜索) has appointed Prista Charuworn, MD, as Chief Medical Officer to accelerate clinical development of its first-in-class SIK3 (搜索) inhibitor COL-5671 (搜索).
Dr. Charuworn brings extensive immunology drug development experience from Gilead, AstraZeneca, Amgen, and Zai Lab, including treatments for inflammatory bowel disease and dermatologic indications.
COL-5671 (搜索) demonstrated a favorable safety profile and promising pharmacokinetic and pharmacodynamic properties in a recently completed first-in-human study.
Coultreon Biopharma (搜索), a clinical-stage biotechnology company developing best-in-class immunology therapies, has appointed Prista Charuworn, MD, as Chief Medical Officer. The announcement, made on August 18, 2026 from Leuven, Belgium, positions the company to accelerate the clinical development of COL-5671 (搜索), its first-in-class SIK3 (搜索) inhibitor.
Dr. Charuworn completed fellowships in gastroenterology and transplant hepatology at Stanford and brings extensive industry experience from roles at Gilead, AstraZeneca, Amgen, and Zai Lab, where she led the development of numerous drugs, including treatments for inflammatory bowel disease and dermatologic indications. Immediately prior to joining Coultreon, Dr. Charuworn served as the Global Head of Neuroscience and Immunology at Zai Lab.
"I'm excited to join Coultreon at a pivotal time as the company prepares for clinical studies in ulcerative colitis (搜索) and psoriasis (搜索)," said Dr. Charuworn. "COL-5671 (搜索) generated compelling data in a recently completed first-in-human study, demonstrating a favorable safety profile and highly promising pharmacokinetic and pharmacodynamic properties. These findings reinforce its potential as a convenient once-daily oral therapy for patients across a spectrum of inflammatory diseases."
Advancing COL-5671 into Phase II Development
Coultreon CEO Pierre Raboisson emphasized the strategic significance of the appointment. "The appointment of Prista as Chief Medical Officer marks an important milestone for Coultreon as we strengthen our position as a leader in autoimmune disease innovation and progress COL-5671 (搜索) into Phase II development," he commented.
Raboisson added that Dr. Charuworn's "extensive experience developing drugs for a variety of inflammatory diseases, combined with her excellent understanding of disease biology, will be critical to executing our ambitious development plans and ensuring timely, high-quality clinical data."
A First-in-Class SIK3 Inhibitor
COL-5671 (搜索) is a highly selective SIK3 (搜索) (salt-inducible kinase 3) inhibitor in clinical development for autoimmune diseases, with broad potential applicability across multiple immune-mediated conditions. Coultreon's pipeline is anchored by its leadership in salt-inducible kinase (SIK) biology, with a focus on selectively modulating key inflammatory pathways to deliver broader and more durable disease control.
The company leverages deep expertise in disease biology, drug discovery, and translational science to select the optimal therapeutic modality to address underlying disease biology with best-in-class therapies. Coultreon is developing best-in-class therapies targeting clinically validated pathways across immunology and metabolic diseases.